CASI Obtains Permission for China Phase II Cancer Trial

CASI Pharma, a US-China cancer drug company formerly known as EntreMed, received CFDA permission to conduct a Phase II trial of its lead molecule, ENMD-2076, in soft tissue sarcoma patients. It is the second indication in China for ENMD-2076, which was approved in July to begin a Phase II trial in patients with triple-net negative breast cancer. CASI has also filed to begin a trial of the drug in advanced ovarian clear cell carcinoma. All three are expansions of US trials. More details.... Stock Symbol: (NSDQ: CASI) Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.